| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, ... New England Journal of Medicine 353 (16), 1659-1672, 2005 | 6563 | 2005 |
| Trastuzumab emtansine for HER2-positive advanced breast cancer S Verma, D Miles, L Gianni, IE Krop, M Welslau, J Baselga, M Pegram, ... New England journal of medicine 367 (19), 1783-1791, 2012 | 4095 | 2012 |
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer J Baselga, J Cortés, SB Kim, SA Im, R Hegg, YH Im, L Roman, JL Pedrini, ... New England Journal of Medicine 366 (2), 109-119, 2012 | 3089 | 2012 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2925 | 2017 |
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ... New England journal of medicine 372 (8), 724-734, 2015 | 2275 | 2015 |
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ... The lancet 369 (9555), 29-36, 2007 | 1955 | 2007 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ... The Lancet 379 (9816), 633-640, 2012 | 1579 | 2012 |
| Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer G Von Minckwitz, M Procter, E De Azambuja, D Zardavas, M Benyunes, ... New England Journal of Medicine 377 (2), 122-131, 2017 | 1453 | 2017 |
| 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial D Cameron, MJ Piccart-Gebhart, RD Gelber, M Procter, A Goldhirsch, ... The Lancet 389 (10075), 1195-1205, 2017 | 1070 | 2017 |
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial L Gianni, U Dafni, RD Gelber, E Azambuja, S Muehlbauer, A Goldhirsch, ... The lancet oncology 12 (3), 236-244, 2011 | 800 | 2011 |
| A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy MD Green, H Koelbl, J Baselga, A Galid, V Guillem, P Gascon, S Siena, ... Annals of Oncology 14 (1), 29-35, 2003 | 737 | 2003 |
| 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial A Goldhirsch, RD Gelber, MJ Piccart-Gebhart, E De Azambuja, M Procter, ... The Lancet 382 (9897), 1021-1028, 2013 | 652 | 2013 |
| Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind … SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, ... The Lancet Oncology 18 (10), 1360-1372, 2017 | 484 | 2017 |
| Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial M Untch, RD Gelber, C Jackisch, M Procter, J Baselga, R Bell, D Cameron, ... Annals of oncology 19 (6), 1090-1096, 2008 | 250 | 2008 |
| Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative … L Gianni, J Baselga, W Eiermann, V Guillem Porta, V Semiglazov, A Lluch, ... Clinical Cancer Research 11 (24), 8715-8721, 2005 | 236 | 2005 |
| Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium J Bellmunt, V Guillem, L Paz-Ares, JL Gonzalez-Larriba, J Carles, ... Journal of clinical oncology 18 (18), 3247-3255, 2000 | 224 | 2000 |
| HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up A Goldhirsch, M Piccart, M Procter, E De Azambuja, H Weber, M Untch, ... Annals of Oncology 23, ixe2, 2012 | 97 | 2012 |
| European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide … L Gianni, J Baselga, W Eiermann, V Guillem Porta, V Semiglazov, A Lluch, ... Journal of Clinical Oncology 23 (16_suppl), 513-513, 2005 | 97 | 2005 |
| Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study J Cortes, S Di Cosimo, MA Climent, H Cortés-Funes, A Lluch, P Gascon, ... Clinical Cancer Research 15 (1), 307-314, 2009 | 79 | 2009 |
| AACR cancer progress report 2013 CL Sawyers, C Abate-Shen, KC Anderson, A Barker, J Baselga, ... Clinical cancer research 19 (20_Supplement), S1-S98, 2013 | 71 | 2013 |
